Other Cancer

An advanced type of cancer radiation is more successful than traditional radiation in avoiding dry mouth when treating head and neck cancers, but it is unknown whether the treatment is better or worse at reducing the size of tumors, according to a new comparative effectiveness review funded by HHS' Agency for Healthcare Research and Quality.

Scientists discuss in 'Importance of achieving a complete response in multiple myeloma, and the impact of novel agents' new findings in myeloma. The goal of treatment for multiple myeloma (MM) is to improve patients' long-term outcomes. One important factor that has been associated with prolonged progression-free and overall survival is the quality of response to treatment, particularly achievement of a complete response (CR), researchers in the United States report.

ARIAD Pharmaceuticals, Inc. announced that the independent Data Monitoring Committee (DMC) of the Phase 3 SUCCEED trial has completed the second interim efficacy analysis as specified in the study protocol and has recommended that the randomized, placebo-controlled trial of oral ridaforolimus in patients with metastatic sarcomas continue to its final analysis, without modification to the study protocol.

Smokers who don't quit before radiation therapy for throat, mouth and other head and neck cancers fair significantly worse than those who do, research from the UC Davis Cancer Center has found.

New research shows genes that make smokers more likely to develop chronic obstructive pulmonary disease (COPD), or emphysema, are also closely linked to an increased likelihood of developing lung cancer, according to studies presented today at the American Thoracic Society's annual meeting.

A University of Rochester study helps to explain why men get liver cancer more often than women and opens the door for a new treatment pathway, by showing a direct link between the androgen receptor, which is more active in men, and the hepatitis B virus as it relates to the deadly cancer.

Lilly released results today from a Phase II study evaluating Lilly Oncology's tasisulam, a novel anti-cancer agent, in patients with metastatic melanoma, the deadliest form of skin cancer.(1) Study results will be presented during the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, Ill. on June 6, 2010.

Celldex Therapeutics, Inc. announced that the first patient has been screened in a randomized Phase 2 study of the Company's novel, first-in- class antibody-based vaccine candidate from its Precision Targeted Immunotherapy (PTI) platform.

A few years ago a thirsty Angela Cunningham walked into a convenience store and was disappointed in her choices for a drink. She saw the row of fountain drinks and coolers of other bottled options and wondered about health aspects of them all. She would look at the ingredient list on the labels and found sugars, artificial sweeteners or preservatives and additives she didn't want.

Carrie Greene's cancer doctor called her on a Saturday morning a few months ago and said he wanted to change her chemotherapy treatment. What do you think about losing your hair, he asked. Greene, 41, who has recurring breast cancer, had already been through that. Twice. One of the worst -- or funniest -- moments came when her 5-year-old daughter yanked off her wig in front of all the kids at day care.